การแพทย์แบบแม่นยำและโรคมะเร็ง

Jarunya  Ngamkham; Thainsang  Phansri; Thitaporn  Pukhan

Authors

Jarunya Ngamkham Basic Research Section, Research and Technology Assessment Division, National Cancer Institute
Thainsang Phansri Basic Research Section, Research and Technology Assessment Division, National Cancer Institute
Thitaporn Pukhan Basic Research Section, Research and Technology Assessment Division, National Cancer Institute

Keywords:

precision medicine, personal medicine, cancer

Abstract

Precision medicine in oncology represents a modern approach that tailors diagnosis and treatment to the specific characteristics of each patient. This strategy involves providing effective medications at the most appropriate doses and times, personalized for each individual. The analysis of molecular profiles, such as genetic, proteomic, and metabolomic data from cancer samples, combined with patient health data, is essential for identifying potential therapeutic targets and guiding the monitoring of targeted treatments. Advanced technologies like whole-genome sequencing, RNA sequencing, behavioral data, environmental factors, and comprehensive health data are critical tools that help physicians make informed decisions and improve treatment outcomes for cancer patients. Precision medicine also extends to supportive care, enhancing the prognosis of patients with malignancies. However, access to this approach may be limited in certain areas due to a lack of advanced technology and specialized expertise. Despite these challenges, precision medicine remains a promising trend that aims to improve patient-specific care and treatment by utilizing individualized health data to maximize the effectiveness of current therapeutic interventions.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394-424.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

International Agency for Research on Cancer. The Global Cancer Observatory. [Internet]. [cited 2024 June 20]. Available from: http://globocan.iarc.fr/factsheet.asp.

Dixon K, Kopras E. Genetic alteration and DNA repair in human carcinogenesis. Semin Cancer Biol. 2004;14(6):441-8.

Vadlapatha RK, Vadlapudi AD, Pal D, Mitra AK. Mechanism of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transports and metabolizing enzymes. Curr Pharm Des. 2013;19(40):7126-44.

Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, et al. Personalized Medicine: Recent Progress in Cancer Therapy. Cancers (Basel). 2020;12(4):1009.

Naithani N, Atal AT, Tilak T V S V G K, Vasudevan B, Misra P, Sinha S. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021;77(3):258-62.

McGrath S, Ghersi D. Building towards precision medicine: empowering medical professionals for the next revolution. BMC Med Genomics. 2016;9(1):23.

Naithani N, Sinha S, Misra P, Vasudevan B, Sahu R. Precision medicine: Concept and tools. Med J Armed Forces India. 2021;77(3):249–57.

Junior HLR, Novaes LAC, Datorre JG, Moreno DA, Reis RM. Role of Polygenic Risk Score in Cancer Precision Medicine of Non-European Populations: A Systematic Review. Curr Oncol. 2022;29(8):5517-38.

Koulis C, Yap R, Engel R, Jardé T, Wilkins S, Solon G, et al. Personalized Medicine Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers (Basel). 2020;12(4):812.

Bonkhoff AK, Grefkes C. Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence. Brain. 2022;145(2):457-60.

Noyes JD, Mordi IR, Doney AS, Jamal R, Lang CC. Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs. Diseases. 2021;9(3):55.

Schwartzberg L, Kim ES, Liu D, Schrag D. Precision Oncology: Who, How, What, When, and When Not?. Am Soc Clin Oncol Educ Book. 2017;37:160-9.

Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304-51.

Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268-74.

Murciano-Goroff YR, Suehnholz SP, Drilon A, Chakravarty D. Precision Oncology: 2023 in Review. Cancer Discov. 2023;13(12):2525-47.

Marcus PM, Pashayan N, Church TR, Doria-Rose VP, Gould MK, Hubbard RA, et al. Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. Cancer Epidemiol Biomarkers Prev. 2016;25(11):1449-57.

Bode AM, Dong Z. Recent advances in precision oncology research. npj Precision Oncol. 2018;2(1):11.

Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Siddique B, Mahasirimongkol S, Teerawattananon Y. Economic evaluation of HLA-B*15:02 screening for carbamazepine induced severe adverse drug reactions in Thailand. Epilepsia. 2013;54(9):1628-36.

Sukasem C. Pharmacogenetic Markers to Predict Drug-induced Allergic Reactions. Thai Pharm Health Sci J. 2009;4(4):532-44.

Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines. 2024;12(8):1801.

Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation. Science. 2013;340(6132):622-6.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science. 2013;340(6132):626-30.

Mascaux C, Tomasini P, Greillier L, Barlesi F. Personalised medicine for non-small cell lung cancer. Eur Respir Rev. 2017;26(146):170066.

Dessai A, Nayak UY, Nayak Y. Precision nanomedicine to treat non-small cell lung cancer. Life Sci. 2024;346:122614.

Wang X, Zhong W, Bu J, Li Y, Li R, Nie R, et al. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer. Mol Carcinog. 2019;58(5):674-84.

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.

Schiffman M, Wentzensen N. A suggested approach to simplify and improve cervical screening in the United States. J Low Genit Tract Dis. 2016;20(1):1-7.

Andrikou K, Rossi T, Verlicchi A, Priano I, Cravero P, Burgio MA. Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer. Int J Mol Sci. 2023;24(22):16085.

Lim C, Mra A, Suliong C, Rao CV, Aung T, Sieman J, et al. Recent Advances in Breast Cancer Diagnosis Entering an Era of Precision Medicine. BJMS. 2018;13(1):3-9.

National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(1):395-409.

Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119(21):3976-83.

Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9.

Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. HER2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6(1):123.

Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992;47(2):179-85.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-9.

Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small-cell lung cancer: updated survival analysis of the AVAPERL

(MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044-52.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-45.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005;37(12):1315-6.

Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. Erlotinib resistance in lung cancer: Current progress and future perspectives. Front Pharmacol. 2013;4:42680.

Tong JS, Zhang QH, Wang ZB, Li S, Yang CR, Fu XQ, et al. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway. PLoS ONE. 2010;5(11):e15408.

Avvaru SP, Noolvi MN, Aminbhavi TM, Chkraborty S, Dash A, Shukla SS. Aromatase inhibitors evolution as potential class of drugs in the treatment of postmenopausal breast cancer women. Mini Rev Med Chem. 2018;18(8):609-21.

Mazo C, Barron S, Mooney C, Gallagher WM. Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER Positive, HER2-Negative Breast Cancer Patients. Cancers (Basel). 2020;12(5):1133.

Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011;141(5):1762-72.

Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2(2):247-56.